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Abstract
Background: A2143G mutation of 23S rRNA gene of H. pylori results in clarithromycin (CLR)
resistance. To investigate the prevalence of the CLR resistance-related A2143G mutation of the H.
pylori-specific 23S rRNA gene in Chinese subjects with and without CLR use history, 307 subjects
received the treatment with amoxicillin and omeprazole (OA) and 310 subjects received a placebo
in 1995, and 153 subjects received a triple therapy with OA and CLR (OAC) in 2000. DNA was
extracted from fasting gastric juice at the end of the intervention trial in 2003. H. pylori infection
was determined by H. pylori-specific  23S rRNA PCR, ELISA, and13C-urea breath test assays.
Mutations of the 23S rRNA gene were detected by RFLP assays.
Results: The presence of 23S rRNA due to H. pylori infection in the OA group remained lower than
that in the placebo group 7.3 yrs after OA-therapy [51.1% (157/307) vs. 83.9% (260/310), p =
0.0000]. In the OAC group, the 23S rRNA detection rate was 26.8% (41/153) three yrs after OAC-
treatment. The A2143G mutation rate among the 23S rRNA-positive subjects in the OAC group
[31.7% (13/41)] was significantly higher than that in the OA group [10.2% (16/157)] and the placebo
group [13.8% (36/260)]. The frequency of the AAGGG → CTTCA (2222–2226) and AACC →
GAAG (2081–2084) sequence alterations in the OAC group was also significantly higher than those
in the OA group and the placebo group.
Conclusion: Primary prevalence of the A2143G mutation was 10~14% among Chinese population
without history of CLR therapy. Administration of CLR to eliminate H. pylori infection increased
the prevalence of the A2143G mutation in Chinese subjects (32%) significantly.
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Background
Helicobacter pylori (H. pylori) infection occurs worldwide.
The prevalence of infection by H. pylori varies greatly
among countries, with over a 70% infection rate in many
developing countries compared to 20% to 50% in most
industrialized nations. H. pylori infection can lead to gas-
tritis, duodenal and gastric ulcer, gastric carcinoma, and
gastric lymphoma [1-3]. Gastric cancer risks can be
reduced by up to 60% by eradication of H. pylori infection
through primary prevention, thus affecting approximately
800,000 gastric cancer patients worldwide [4,5].
Currently, a seven-day, triple-drug regimen has been rec-
ommended as one of the first-line therapies for H. pylori
management [6,7]. This treatment includes omeprazole
(a proton-pump inhibitor), clarithromycin (CLR), and
amoxicillin. However, this therapy is being investigated
because of increased eradication failures due to the preva-
lence of CLR-resistant (CLRr) H. pylori infections. Many
studies have shown that between 0–50% of H. pylori iso-
lates were CLRr, which leads to a need for long term
assessment of the efficacy of CLR in the triple-drug regi-
men [8,9]. It is well known that the abuse of macrolide
antibiotics including CLR might lead to CLR resistant
forms of H. pylori. Whether an optimal therapy containing
CLR for H. pylori eradication would contribute to the prev-
alence of CLRr H. pylori infection was not well investigated
among the Chinese population.
From 1995 to 2003, a randomized, double blind and pla-
cebo-controlled intervention trial was conducted in a
high-risk population for gastric cancer in Linqu County,
Shandong Province of China [10]. One of the three treat-
ments of H. pylori infection in this study was a dual-drug
therapy with omeprazole and amoxicillin (OA), since the
triple-drug regimen was not available in 1995. This study
focused on subjects who were H. pylori seropositive at
baseline. In 2000, a triple therapy consisting of OA and
CLR (OAC) was applied to subjects who were H. pylori
seronegative at baseline and subsequently found to be
13C-urea breath test (13C-UBT)-positive, according to
instruction of the Ethic Committee of the Beijing Institute
for Cancer Research and the U.S. National Cancer Insti-
tute (NCI).
In H. pylori infection, resistance to CLR is mostly due to
the presence of A2143G and A2142G/C point mutations
of the 23S rRNA gene [8,11,12]. We recently reported that
the A2143G mutation was a late event in the development
of CLR resistance of H. pylori 26695 [13]. The global aver-
age mutation frequency for the A2143G and A2142G
mutations causing CLR resistance of H. pylori were 69.8%
and 11.7%, respectively [8]. Herein, we report the preva-
lence of the A2143G and A2142G mutations of the H.
pylori-specific 23S rRNA gene among these subjects treated
with regimens with or without CLR after eradication of H.
pylori infection.
Results
Genomic DNA was extracted from 770 of pre-fixed fasting
gastric juice samples as described in the Method section.
To determine both the presence of H. pylori infection and
prevalence of CLRr, a H. pylori-specific  23S rRNA PCR
assay was developed. H. pylori infection was detected in
59.5% of analyzed subjects by the PCR assay as compared
to 68.1% and 71.0% by 13C-UBT and ELISA, respectively
(Table 1). If the combined results of 13C-UBT and ELISA
assays were used as the gold standard [both positive (H.
pylori infection) or both negative (not infected)], the PCR
Table 1: Comparisons of sex, age, H. pylori infection, and mutations of the 23S rRNA gene between subjects with and without CLR use 
history
Groups Placebo OA OAC (Total)
CLR use history - - +
Case No. 310 307 153 770
Sex ratio (M:F) 1:1.00 1:1.13 1:0.82 1:1.01
Age (yrs) (Mean ± SD) 45.3 ± 8.4 45.0 ± 8.4 45.7 ± 8.6 45.2 ± 8.5
H. pylori-positive rate in 2003 (%) 13C-UBT 90.6 (280/309) 54.11 (166/307) 53.3 (81/152) 68.1 (527/768)
ELISA 92.5 (283/306) 62.11 (185/298) 44.12 (64/145) 71.0 (532/749)
23S rRNA 83.9 (260/310) 51.11 (157/307) 26.82 (41/153) 59.5 (458/770)
Proportion of 2143G-positive H. pylori (%) Total CLRr 13.8 (36/260) 10.2 (16/157) 31.73 (13/41) 14.2 (65/458)
CLRr & s 9.6 (25/260) 6.4 (10/157) 14.6 (6/41) 9.0 (41/458)
Proportion of MboII-RFLP-positive H. pylori (%) 2222CTTCA 0.4 (1/260) 1.9 (3/157) 4.94 (2/41) 1.3 (6/458)
2081GAAG 1.9 (5/260) 1.3 (2/157) 14.65 (4/41) 2.4 (11/458)
1: OA group vs. placebo group, p < 0.0000;
2: OAC group vs. OA group, p < 0.0005;
3: OAC group vs. OA group, OR = 4.09, 95%CI [1.64–10.23]; OAC group vs. placebo group, OR = 2.89, 95%CI [1.28–6.46];
4: OAC group vs. OA group, OR = 2.63, 95%CI [0.30–20.29]; OAC group vs. placebo group, OR = 13.28, 95%CI [0.91–379];
5: OAC group vs. OA group, OR = 8.38, 95%CI [1.25–68.84]; OAC group vs. placebo group, OR = 5.51, 95%CI [1.18–25.12]BMC Microbiology 2008, 8:81 http://www.biomedcentral.com/1471-2180/8/81
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assay's sensitivity and specificity was 83.4% and 75.5%,
respectively. Its Youdens' index was 0.59 (Table 2).
Seven years after the OA treatment, the presence of 23S
rRNA  due to H. pylori infection remained remarkably
lower than that in the placebo group [51.1% (157/307)
vs. 83.9% (260/310), p = 0.0000] (Table 1). Three years
after the triple therapy with CLR, the cumulative H. pylori
infection rate in the OAC group was 26.8% (41/153) by
PCR (Table 1).
To detect the prevalence of CLRr H. pylori infection, a BsaI-
restriction PCR-RFLP assay was developed using the PCR
product of 23S rRNA for detection of the A2143G muta-
tion as illustrated in Fig 1. The A2143G mutation was
detected in 65 of the 458 PCR products, which showed the
presence of H. pylori, by the RFLP assay (Fig 2A). In 41 of
the 65 A2143G-positive cases (63.1%), both the BsaI-sen-
sitive and -insensitive PCR products of 23S rRNA were
observed. For 12 representative samples, results of the
PCR-RFLP assay were consistent with that of sequencing
(Fig 2B).
Table 2: Comparison of accuracy of various assays for detection of H. pylori infection
Assays Sensitivity Specificity Youden's index1
23S rRNA PCR2 83.4% (373/447) 75.5% (114/151) 0.59
13C-UBT3 94.9% (373/393) 70.8% (114/161) 0.66
ELISA4 95.2% (373/392) 63.7% (114/179) 0.59
1: defined as "sensitivity + specificity - 1";
2: both 13C-UBT and ELISA were positive or negative for comparison;
3: both PCR and ELISA were positive or negative for comparison;
4: both PCR and 13C-UBT were positive or negative for comparison.
Schematic diagram for detection of nucleotide alterations of 23S rRNA by PCR-RFLP assays Figure 1
Schematic diagram for detection of nucleotide alterations of 23S rRNA by PCR-RFLP assays. The 23S rRNA 
sequence of H. pylori 26695 was illustrated as the wild-type sequence [GenBank No.: U27270].BMC Microbiology 2008, 8:81 http://www.biomedcentral.com/1471-2180/8/81
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Chromatograms of PCR-RFLP assays and sequencing for detection of nucleotide alterations of 23S rRNA Figure 2
Chromatograms of PCR-RFLP assays and sequencing for detection of nucleotide alterations of 23S rRNA. H. 
Pylori 26695 and CLRr-1 were used as negative and positive control of A2143G mutation. BsaI digestion of the PCR products of 
representative samples was displayed on 8% PAGE gel. The 289 bp A2143G-positive PCR products were cleaved into a 199 bp 
and a 90 bp fragments (A). The A2143G mutation was also confirmed by sequencing of the PCR products of 23S rRNA (B, dis-
played 2140–2154 fragment). H. Pylori 26695 and a 2142G clone were used as negative and positive control of A2142G muta-
tion. MboII digestion of the PCR products of representative samples was displayed on 2% agarose gel. The 289 bp A2142G-
positive PCR products of 2142G were cleaved into an 182 bp and a 107 bp fragments. The PCR product of GJ2040 was cleaved 
into a 164 bp and a 125 bp fragments; and the product of GJ2111 was cleaved into 245 bp and 44 bp fragment(s) (C). The 
A2142G and other mutations were confirmed by sequencing (D). Two new MboII-sensitive sequences were characterized as 
CTTCA (2222–2226) for GJ2040 and GAAG (2081–2084) for GJ2111.BMC Microbiology 2008, 8:81 http://www.biomedcentral.com/1471-2180/8/81
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To detect the A2142G mutation within 23S rRNA, a MboII-
restriction PCR-RFLP assay was also developed (Fig 1). No
A2142G point mutation was observed among 458 sub-
jects with H. pylori infection. However, two new MboII-
RFLP patterns were detected in DNA samples from 17 sub-
jects (Fig 2C): a pattern consisting of a 164 bp and a 125
bp fragment was observed from 11 subjects and another
pattern consisting of a 245 bp and 44 bp fragment was
detected from 6 cases. Sequencing showed that the former
11 cases had a sequence change of AACC → GAAG (2081–
2084) and the latter 6 cases had a sequence change of
AAGGG → CTTCA (2222–2226) (Fig 2D).
To investigate the relationship between the prevalence of
CLRr H. pylori infection and administration of CLR as a
component of an optimal triple therapy, A2143G muta-
tion rates within 23S rRNA in each therapy group were
analyzed (Table 1). The presence of the A2143G mutation
in the OAC group was 3.1 times higher than that in the
OA group [31.7% vs. 10.2%, p = 0.0005; OR 4.09 (95%
CI = 1.64–10.23)] and 2.3 times higher than that in the
placebo group [31.7% vs. 13.8%, p = 0.0040; OR 2.89
(95% CI = 1.28–6.46)]. The difference of the A2143G
mutation rate due to CLR was 21.5% between the OAC
and OA groups. In the OAC group, the co-infection rate
(14.6%) of BsaI-insensitive  H. pylori among subjects
infected with BsaI-sensitive H. pylori was higher than those
in the OA group (6.4%) and the placebo group (9.6%)
but not significant (p = 0.0838 and 0.3258, respectively).
Moreover, the sequence change AAGGG → CTTCA
(2222–2226) in the OAC group was 12.3 times of the pla-
cebo group (4.9% vs. 0.4%, p = 0.0497; OR 13.28, 95% CI
0.91–379); the AACC → GAAG (2081–2084) in the OAC
group was 11.2 times of the OA group (14.6.7% vs. 1.3%,
p = 0.018; OR 8.38, 95% CI 1.25–68.84) and 7.7 times of
the placebo group (14.6% vs. 1.9%, p = 0.002; OR 5.51,
95% CI 1.18–25.12) (Table 1).
Discussion
Among Chinese subjects enrolled in the long term popu-
lation-based trial [10], we found that the proportion of
the primary CLRr related A2143G mutation among 23S
rRNA-positive subjects in the placebo group was 13.8%
(36/260), which was similar to the average reported CLR-
resistant prevalence of 10.5% (35/334) within China:
5.2% (5/96) [14], 9.8% (4/41) [13], 13.5% (12/89) [15],
and 14.8% (16/108) [16]. That the CLRr infection rate in
the OA group was slightly lower than that in the placebo
group (p = 0.274) indicated that the OA treatment for
eradication of H. pylori might reduce the prevalence of pri-
mary CLRr among the treated subjects. Heep et al. reported
that secondary resistance to CLR was up to 50% in a study
of 554 H. pylori isolates after failure of therapy [17]. It is
well recognized that eradication therapy with CLR led to
the prevalence of CLRr H. pylori infection [8,9]. In the
present study, we observed a 31.7% A2143G mutation
rate among H. pylori infected subjects three years after
treatment with CLR, which is significantly higher than
that among subjects without CLR treatment in the OA and
placebo groups (OR = 4.09 and 2.89, respectively). An
optimal way to validate the exact effect of CLR use on the
formation of the secondary CLR resistance was to com-
pare the prevalence of the A2143G mutation among sub-
jects before and after administration of CLR. Because of
the lack of gastric juice samples before eradication ther-
apy, the original mutation status of 23S rRNA in samples
was not available, thus such comparison could not be car-
ried out in the present study. This is a limitation of our
study. The strength of this study was that all of the subjects
in the OAC group had the same CLR treatment history in
2000, and those in the OA and placebo group did not.
Therefore, the prevalence of CLRr  H. pylori infection
among subjects with and without CLR use in the local area
was reliably obtained. These results were useful for evalu-
ation of the exact effect of administration of CLR for erad-
ication of H. pylori on the prevalence of the A2143G
mutation among Chinese subjects.
Unlike indirect assays such as ELISA and 13C-UBT, PCR
assays are direct assays to detect H. pylori infection. Thus,
these assays should result in higher specificity than the
indirect assays. H. pylori colonizes on the apical surface of
stomach's epithelial cells and sheds into gastric juice with
the regular renewal of gastric mucosa. Several PCR assays
based on H. pylori DNA from gastric juice/biopsy sample
were reported for detection of H. pylori infection
[13,18,19]. The possible H. pylori-specific target genes
included ureA, ureB, ureC, ureD, 16S rRNA, and 23S rRNA.
Point mutations of 23S rRNA were closely related to for-
mation of CLR resistance [8,11,12]. Because the PCR
product of 23S rRNA described in this study could be used
as a biomarker to detect H. pylori infection and CLR resist-
ance simultaneously, this assay has advantages over other
PCR-based methodologies. However, the specificity and
sensitivity of the 23S rRNA PCR assay was not evaluated
extensively. No single test is accepted as the standard for
diagnosis of H. pylori infection [20,21]. In the present
study, the status of H. pylori infection was detected by the
23S rRNA PCR assay, 13C-UBT, and ELISA for each subject,
which provided an opportunity to assess the specificity
and sensitivity of these assays. As expected, the highest
specificity was observed for the 23S rRNA PCR assay when
both CUBT and ELISA assays were negative for H. pylori
infection. The Youden's index of the 23S rRNA PCR assay
was similar to that of the ELISA assay but lower than that
of 13C-UBT (Table 2).
Generally, PCR-based assays used to detect H. pylori infec-
tion are considered the most sensitive. However, the sen-
sitivity of the 23S rRNA PCR assay was lower than 13C-BMC Microbiology 2008, 8:81 http://www.biomedcentral.com/1471-2180/8/81
Page 6 of 8
(page number not for citation purposes)
UBT and ELISA in the present study (Table 2). Because the
genomic DNA could not be extracted from gastric juice
samples immediately after collection and that the shed-
ded gastric epithelial cells easily self-decompose, the qual-
ity and amount of DNA extracted is variable between
samples. In this study, fixative was added to gastric juice
samples at the local clinics to prevent degeneration of
DNA, and then the samples were stored at -20°C. These
samples were shipped to the laboratory using dry ice and
stored at -80°C. Although the fixative was removed with
repeated washings before DNA extraction, it is possible
that the quality of the DNA was adversely affected. The fix-
ation process could be omitted if gastric juice samples can
be stored at -80°C immediately after collection. However,
it would be optimal if the DNA were isolated from fresh
samples immediately after collection.
CLRr results mainly from point mutations in the peptidyl-
transferase loop region of 23S rRNA [8,9,11-13]. The most
frequent mutations are A2143G and A2142G [8]. Other
mutations such as A2142C, A2115G, G2141A, and
T2717C might also be associated with CLRr. Recent
reports demonstrated that the A2143G point mutation of
23S rRNA were detected in average of 90% (44 of 49) CLRr
H. pylori isolates from Chinese subjects [13-16,22]. In the
present study, the A2143G mutation was detectable in 65
of 458 23S rRNA PCR products by the BsaI-restriction
PCR-RFLP assay (Table 1). No A2142G mutation was
detected in these samples. These results suggest that the
A2143G may be a very useful CLRr indicator for selection
of optimal therapy against H. pylori infection in China.
In 41 of the 65 A2143G-positive cases (63.1%), both the
BsaI-sensitive and -insensitive 23S rRNA PCR products
was observed. Because the PCR products of the A2143G-
positive control (CLRr-1) were digested by BsaI enzyme
completely in each experiment, partial restriction could
be excluded. Thus, multi-strain H. pylori infection likely
happened among these cases. Sequencing results of 12
representative samples supported the deduction (Fig. 2B).
Isolation of the sensitive and resistant strains from cul-
tures might provide a direct evidence to show the mixed
colonization. Because the experimental conditions at the
local clinics in Linqu County was not adequate to support
primary H. pylori culture, isolation of H. pylori from biop-
sies of stomach was not carried out in the clinical trial. The
high H. pylori infection rate in the local area might con-
tribute to the high co-infection rate of the CLR sensitive
and resistant H. pylori strains.
In addition, two new MboII-RFLP patterns were discovered
in 17 subjects in the present study. Sequencing showed
that 6 of the 17 cases had a sequence change of AAGGG →
CTTCA (2222–2226) and that the remaining 11 cases had
a sequence change of AACC → GAAG (2081–2084). The
A2143G mutation was detected only in 3 of the 15 GAAG-
positive cases (20%). Both the AAGGG → CTTCA (2222–
2226) and AACC → GAAG (2081–2084) alterations are
located around the conserved domain V of 23S rRNA
(2126–2712, equal to Escherichia coli numbering 2042 to
2628), a region closely related to resistance formation of
macrolide antibiotics including CLR [23,24]. It was
reported that the point mutation A2224G might not con-
tribute to the CLR resistance among Japanese [27]. In the
present study, we observed that the presence of the
AAGGG  → CTTCA (2222–2226) and AACC → GAAG
(2081–2084) sequence alterations in OAC group were
significantly higher than those in the OA and placebo
groups (Table 1). The A2143G mutation was detected
only in 2 of the 11 AACC → GAAG (2081–2084) cases
(18.2%). Whether these alterations contribute to CLR
resistance should be investigated further.
Conclusion
The primary prevalence of the CLRr-related A2143G muta-
tion within the 23S rRNA gene as determined by a novel
PCR-RFLP assay is approximately 10~14% among Chi-
nese subjects without CLR use history. Application of
CLR-containing regimen for H. pylori eradication could
increase risk of prevalence of the A2143G mutation signif-
icantly (OR = 3~4).
Methods
Study population and collection of gastric juice samples
All subjects were from those enrolled in the intervention
trial. The experimental design and population of this
intervention trial (trial no. NCI-OH-95-C-N029) have
been described in detail elsewhere [10]. Fasting gastric
juice samples were taken by a side-tube connected to vac-
uum device within the gastroendoscope at the end of the
intervention trial in 2003. All subjects with more than 5
mL of gastric juice were eligible for the present study.
Seven hundred and seventy of gastric juice samples were
collected during the endoscope examination. In the OA
group, 307 subjects with H. pylori seropositive were given
amoxicillin (1000 mg) and omeprazole (20 mg) to take
twice daily for two weeks in 1995, while 310 subjects with
seropositive were given placebo capsules as described
[10]. One hundred and fifty three subjects with H. pylori
seronegative at baseline but were subsequently deter-
mined to be 13C-UBT-positive received a first-line triple
therapy of CLR (500 mg), amoxicillin (1000 mg) and
omeprazole (20 mg) to take twice daily for two weeks,
according to instruction of the Ethic Committee in 2000.
Status of H. pylori infection of each individual was
detected by 13C-UBT and ELISA assays [25,26].
Extraction of genomic DNA from gastric juice samples
To avoid self-decomposition, the shedded gastric mucosa
was fixed immediately after collection of the samples at aBMC Microbiology 2008, 8:81 http://www.biomedcentral.com/1471-2180/8/81
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local clinic in Linqu County. All the collected gastric juice
specimens (5–30 mL) were centrifuged at 10,000 g for 10
min. After centrifugation, the supernatant liquid was
removed leaving ~1 mL residue. The sample was then
resuspended in 2 mL of FAA fixative (ethanol, acetic acid,
and 40% formaldehyde at volume proportion of 9:1:1)
and frozen at -20°C. The collected samples were shipped
with dry ice and stored at -80°C at Etiology Laboratory,
Beijing Institute for Cancer Research, Beijing.
For DNA extraction, the frozen samples were thawed, and
the fixative was removed with 2 × 5 mL aliquots of PBS.
The samples were centrifuged at 10,000 g for 10 min and
the supernatant liquid was removed after each PBS wash.
The sediment was then resuspended in 5 mL of 10% SDS
containing hyaluronidase (final concentration, 20 U/mL)
(Sigma, Inc, USA) and incubated at 37°C for two hours to
digest mucus. Proteinase K (final concentration, 20 U/
mL) (Merck, Inc, Germany) was then added, and the sam-
ple was incubated at 55°C for more than three days until
the desquamated tissue was digested completely. The
DNA in the samples was extracted following a standard
phenol chloroform procedure.
Amplification of the H. pylori-specific 23S rRNA by PCR
A 289 bp fragment of H. pylori chromosomal DNA was
amplified by PCR as reported recently [13]. Briefly, the
23S rRNA gene of H. pylori [GenBank: U27270] was
amplified using the following primers: 5'-GCA TGA ATG
GCG TAA CGA GAT G-3' and 5'-CCC AGT CAA ACT ACC
CAC CAA G-3' (corresponding to 2049–2070 and 2316–
2337 of the 23S rRNA gene, respectively). The 289 bp PCR
products were verified on 2% agarose gel.
RFLP assays
The 289 bp amplicon of 23S rRNA was digested with the
restriction enzymes BsaI  and  MboII  (New England
Biolabs, USA) in order to detect A2143G and A2142G
point mutations, respectively (Fig 1) [13,27]. An 8%
PAGE gel was used to observe the restriction products. The
amplicon of H. pylori 26695 strain was used as negative
control. The CLRr-1 strain selected from H. pylori 26695
[by CLR] contained an A2143G point mutation and was
used as one positive control [13]. An A2142G point muta-
tion was introduced into the amplicon of H. pylori 26695
by mutation PCR. One of the A2142G clones (confirmed
by sequencing) was used as another positive control.
DNA sequencing
PCR products of H. pylori 23S rRNA were sequenced by an
ABI Prism 377 sequencer (PE Biosystems, USA) with fluo-
rescent dye terminators.
Statistical analysis
For statistical analysis, the χ2 test was used to evaluate the
significance of differences of H. pylori infection and CLRr
frequency between CLR and control groups. All p-values
were two-sided and p < 0.05 was considered statistically
significant. All analyses were performed with SAS software
version 8.0.
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